RYAH Group Inc. Well Positioned as Data Continues to Shape Future of Medical Research

February 8, 2021 14:27:46
  • Recent article finds that data remains one of main drivers of medical research in 2021.
  • New technologies employing AI powered by big data provide new solutions for tackling health problems, expand possibilities of clinical research
  • RYAH combines power of devices combined with data to impact future of medical research to advance treatment of various medical conditions

A recent Becker’s Hospital Review article cites 10 emerging trends in health IT that will shape this field in 2021, reporting that big data management is becoming a need as the use of artificial intelligence (“AI”) and machine learning in healthcare continues to blossom (https://ibn.fm/bMPIY). With the increasing demand in the medical space for application of analytics powered by novel technology, RYAH Group is set to benefit as a leading digital health care analytics and technology company committed to advancing the world’s transition to remote-health solutions and data analytics in patient treatments.

With the digitalization of medical records and improved medical analytics coupled with a proliferation of wearables, there has been an explosion of medical data over the past decade. That explosion has led to a revolution in medical and health-care research. The vast amount of data available for analysis enables AI-powered algorithms to transform the medical field more than ever before, helping to define what is healthy and to diagnose, treat and prevent any deviations from the ideal standard. The applications go beyond the individual level, offering solutions to tackle health challenges at the level of humanity.

Blossoming of artificial intelligence and machine learning in health care, driven by a combination of wearables and other biomedical devices, will continue to transform clinical research and treatment protocols as well as increase the virtual-care capabilities of health providers, the article observes. “AI is not new in healthcare,” the article notes. “But in the last year AI became crucial in developing predictive models for COVID-19 cases spreading across the country. . . . The field will continue to evolve and become more integrated with clinical care in the coming years.”

Technological advancements make these developments possible as the data continue to be the major trend shaping medical research. The article reports that big data management becomes mission critical as the pandemic highlighted the need for centralized and efficient data management. The data-gathering and reporting efforts accelerated during the virus outbreak, propelling organizations of all sizes to consider cloud implementations to securely store and coordinate data as secure medical research becomes a priority.

As a company committed to leveraging the value of health devices combined with data to positively impact the future treatment of patients with various medical conditions, RYAH is set to be at the forefront of the data-driven medical future. Indispensable in modern medical research, data is at the core of the company’s strategic approach.

RYAH aggregates data collected by its product ecosystem, creating a HIPAA-compliant database enhanced by AI-powered solutions designed to analyze and clarify complex relationships between peer-reviewed research, consumer feedback and therapeutic plants. As the company specializing in unlocking data in the complete therapeutic plant lifecycle – from seed to consumption – RYAH appears strategically placed in the $100.3 billion medical plant market, with the potential to capitalize on growth opportunities enabled by both the IoT and data intelligence (https://ibn.fm/zlZou).

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.